Follow
Andrew L. Hopkins
Andrew L. Hopkins
CEO, Exscientia
Verified email at exscientia.co.uk - Homepage
Title
Cited by
Cited by
Year
How many drug targets are there?
JP Overington, B Al-Lazikani, AL Hopkins
Nature reviews Drug discovery 5 (12), 993-996, 2006
44942006
The druggable genome
AL Hopkins, CR Groom
Nature reviews Drug discovery 1 (9), 727-730, 2002
41082002
Network pharmacology: the next paradigm in drug discovery
AL Hopkins
Nature chemical biology 4 (11), 682-690, 2008
39652008
Ligand efficiency: a useful metric for lead selection
AL Hopkins, CR Groom, A Alex
Drug discovery today 9 (10), 430-431, 2004
20492004
Quantifying the chemical beauty of drugs
GR Bickerton, GV Paolini, J Besnard, S Muresan, AL Hopkins
Nature chemistry 4 (2), 90-98, 2012
16892012
Network pharmacology
AL Hopkins
Nature biotechnology 25 (10), 1110-1111, 2007
12662007
Navigating chemical space for biology and medicine
C Lipinski, A Hopkins
Nature 432 (7019), 855-861, 2004
12252004
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
10602014
Global mapping of pharmacological space
GV Paolini, RHB Shapland, WP van Hoorn, JS Mason, AL Hopkins
Nature biotechnology 24 (7), 805-815, 2006
9142006
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis, RM Rodriguiz, XP Huang, ...
Nature 492 (7428), 215-220, 2012
8362012
Can we rationally design promiscuous drugs?
AL Hopkins, JS Mason, JP Overington
Current opinion in structural biology 16 (1), 127-136, 2006
5832006
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors
AL Hopkins, J Ren, RM Esnouf, BE Willcox, EY Jones, C Ross, ...
Journal of Medicinal Chemistry 39 (8), 1589-1600, 1996
4301996
Genomic-scale prioritization of drug targets: the TDR Targets database
F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ...
Nature reviews Drug discovery 7 (11), 900-907, 2008
3552008
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this …
RM Esnouf, J Ren, AL Hopkins, CK Ross, EY Jones, DK Stammers, ...
Proceedings of the National Academy of Sciences 94 (8), 3984-3989, 1997
2761997
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design
J Ren, R Esnouf, A Hopkins, C Ross, Y Jones, D Stammers, D Stuart
Structure 3 (9), 915-926, 1995
2701995
Predicting promiscuity
AL Hopkins
Nature 462 (7270), 167-168, 2009
1932009
Fragment screening by surface plasmon resonance
I Navratilova, AL Hopkins
ACS Medicinal Chemistry Letters 1 (1), 44-48, 2010
1752010
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants
AL Hopkins, J Ren, H Tanaka, M Baba, M Okamato, DI Stuart, ...
Journal of medicinal chemistry 42 (22), 4500-4505, 1999
1661999
A crowdsourcing evaluation of the NIH chemical probes
TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ...
Nature chemical biology 5 (7), 441-447, 2009
1392009
Validity of ligand efficiency metrics
CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ...
ACS medicinal chemistry letters 5 (6), 616-618, 2014
1312014
The system can't perform the operation now. Try again later.
Articles 1–20